Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases

Experimental and Molecular Pathology

Volumn 93, Issue 3, 2012, Pages 428-433

  Safavi, Farinaz ^a   Rostami, Abdolmohamad ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autoimmune diseases; BBI; EAE; Inflammation; Multiple sclerosis; Serine protease inhibitors; Serine proteases

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALPHA 1 ANTITRYPSIN; BOWMAN BIRK INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ACIDITY; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL CULTURE; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON CARCINOMA; COMPLEMENT DEFICIENCY; CYTOKINE PRODUCTION; DISEASE MODEL; ENZYME INHIBITION; HUMAN; IMMUNOREGULATION; INFLAMMATION; LEUKOPLAKIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PROSTATE CANCER; REMISSION; RESPIRATORY TRACT ALLERGY; TEMPERATURE;

AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

GLYCINE MAX;

EID: 84870662548     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.09.014     Document Type: Article

References (75)

1. Adkison A.M., Raptis S.Z., Kelley D.G., Pham C.T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. The Journal of Clinical Investigation 2002, 109:363-371.
2. Armstrong W.B., Kennedy A.R., Wan X.S., Taylor T.H., Nguyen Q.A., Jensen J., Thompson W., Lagerberg W., Meyskens F.L. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clinical Cancer Research 2000, 6:4684-4691.
3. Asero R., Riboldi P., Tedeschi A., Cugno M., Meroni P. Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation. Autoimmunity Reviews 2007, 7:71-76.
4. Bao L., Haas M., Boackle S.A., Kraus D.M., Cunningham P.N., Park P., Alexander J.J., Anderson R.K., Culhane K., Holers V.M., Quigg R.J. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. Journal of Immunology 2002, 168:3601-3607.
5. Beinrohr L., Dobo J., Zavodszky P., Gal P. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends in Molecular Medicine 2008, 14:511-521.
6. Billings P.C., Newberne P.M., Kennedy A.R. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990, 11:1083-1086.
7. Birk Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans. International Journal of Peptide and Protein Research 1985, 25:113-131.
8. Blaber S.I., Ciric B., Christophi G.P., Bernett M.J., Blaber M., Rodriguez M., Scarisbrick I.A. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. The FASEB Journal 2004, 18:920-922.
9. Bowlus C.L., Ahn J., Chu T., Gruen J.R. Cloning of a novel MHC-encoded serine peptidase highly expressed by cortical epithelial cells of the thymus. Cellular Immunology 1999, 196:80-86.
10. Caggana M., Kennedy A.R. c-fos mRNA levels are reduced in the presence of antipain and Bowman-Birk inhibitor. Carcinogenesis 1989, 10:2145-2148.
11. Chen Y.W., Huang S.C., Lin-Shiau S.Y., Lin J.K. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26:1296-1306.
12. Cheronis J.C., Repine J.E. Proteases, Protease Inhibitors, and Protease-derived Peptides: Importance in Human Pathophysiology and Therapeutics 1993, 2-25. Birkhauser Verlag, Basel; Boston.
13. Cho E.Y., Choi S.C., Lee S.H., Ahn J.Y., Im L.R., Kim J.H., Xin M., Kwon S.U., Kim D.K., Lee Y.M. Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis. International Immunopharmacology 2011, 11:412-417.
14. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., Ma L., Watowich S.S., Jetten A.M., Tian Q., Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
15. Clark D.A., Day R., Seidah N., Moody T.W., Cuttitta F., Davis T.P. Protease inhibitors suppress in vitro growth of human small cell lung cancer. Peptides 1993, 14:1021-1028.
16. Clemente A., Moreno F.J., Marin-Manzano Mdel C., Jimenez E., Domoney C. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Molecular Nutrition & Food Research 2010, 54:396-405.
17. Clemente A., Sonnante G., Domoney C. Bowman-Birk inhibitors from legumes and human gastrointestinal health: current status and perspectives. Current Protein & Peptide Science 2011, 12:358-373.
18. Coughlan A.M., Freeley S.J., Robson M.G. Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Immunology 2012, 169:229-237.
19. Cua D.J., Hutchins B., LaFace D.M., Stohlman S.A., Coffman R.L. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. Journal of Immunology 2001, 166:602-608.
20. Dai H., Ciric B., Zhang G.X., Rostami A. Bowman-Birk Inhibitor attenuates experimental autoimmune encephalomyelitis by delaying infiltration of inflammatory cells into the CNS. Immunologic Research 2011, 51:145-152.
21. Dai H., Ciric B., Zhang G.X., Rostami A. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. Journal of Neuroimmunology 2012, 245:1-7.
22. Dinarello C.A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. The Journal of Allergy and Clinical Immunology 1999, 103:11-24.
23. Ghayur T., Banerjee S., Hugunin M., Butler D., Herzog L., Carter A., Quintal L., Sekut L., Talanian R., Paskind M., Wong W., Kamen R., Tracey D., Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997, 386:619-623.
24. Gran B., Tabibzadeh N., Martin A., Ventura E.S., Ware J.H., Zhang G.X., Parr J.L., Kennedy A.R., Rostami A.M. The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. Multiple Sclerosis 2006, 12:688-697.
25. Guma M., Ronacher L., Liu-Bryan R., Takai S., Karin M., Corr M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis and Rheumatism 2009, 60:3642-3650.
26. Horl W.H., Heidland A. Proteases II: Potential Role in Health and Disease 1987, 8-12. Plenum Press, New York.
27. Joanitti G.A., Azevedo R.B., Freitas S.M. Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds. Cancer Letters 2010, 293:73-81.
28. Karpuzoglu E., Gogal R.M.Jr, Ansar Ahmed S. Serine protease inhibitor, 4-(2-aminoethyl)-benzene sulfonyl fluoride, impairs IL-12-induced activation of pSTAT4beta, NFkappaB, and select pro-inflammatory mediators from estrogen-treated mice. Immunobiology 2011, 216:1264-1273.
29. Kennedy A.R., Troll W. Overview: anti-carcinogenic activity of protease inhibitors. Protease Inhibitors as Cancer Chemopreventive Agents 1993, 9-64. Plenum Press, New York.
30. Kennedy A.R., Wan X.S. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 2002, 50:125-133.
31. Kennedy A.R., Beazer-Barclay Y., Kinzler K.W., Newberne P.M. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Research 1996, 56:679-682.
32. Kobayashi S.D., Voyich J.M., Burlak C., DeLeo F.R. Neutrophils in the innate immune response. Archivum Immunologiae et Therapiae Experimentalis 2005, 53:505-517.
33. Korkmaz B., Horwitz M.S., Jenne D.E., Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacological Reviews 2010, 62:726-759.
34. Lee S.R., Guo S.Z., Scannevin R.H., Magliaro B.C., Rhodes K.J., Wang X., Lo E.H. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neuroscience Letters 2007, 417:1-5.
35. Lefrancais E., Roga S., Gautier V., Gonzalez-de-Peredo A., Monsarrat B., Girard J.P., Cayrol C. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1673-1678.
36. Lewis E.C. Expanding the clinical indications for alpha-1-antitrypsin therapy. Molecular Medicine 2012, (Epub ahead of print). 10.2119/molmed.2011.00196.
37. Lichtenstein G.R., Deren J.J., Katz S., Lewis J.D., Kennedy A.R., Ware J.H. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Digestive Diseases and Sciences 2008, 53:175-180.
38. Liu Z., Shapiro S.D., Zhou X., Twining S.S., Senior R.M., Giudice G.J., Fairley J.A., Diaz L.A. A critical role for neutrophil elastase in experimental bullous pemphigoid. The Journal of Clinical Investigation 2000, 105:113-123.
39. Losso J.N. The biochemical and functional food properties of the Bowman-Birk inhibitor. Critical Reviews in Food Science and Nutrition 2008, 48:94-118.
40. Magnusson S.E., Pejler G., Kleinau S., Abrink M. Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. The FASEB Journal 2009, 23:875-882.
41. Manicone A.M., McGuire J.K. Matrix metalloproteinases as modulators of inflammation. Seminars in Cell & Developmental Biology 2008, 19:34-41.
42. Maryanoff B.E., de Garavilla L., Greco M.N., Haertlein B.J., Wells G.I., Andrade-Gordon P., Abraham W.M. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. American Journal of Respiratory and Critical Care Medicine 2010, 181:247-253.
43. McCormick D.L., Johnson W.D., Bosland M.C., Lubet R.A., Steele V.E. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutrition and Cancer 2007, 57:184-193.
44. Messadi D.V., Billings P., Shklar G., Kennedy A.R. Inhibition of oral carcinogenesis by a protease inhibitor. Journal of the National Cancer Institute 1986, 76:447-452.
45. Mizutani H., Schechter N., Lazarus G., Black R.A., Kupper T.S. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. The Journal of Experimental Medicine 1991, 174:821-825.
46. Moy L.Y., Billings P.C. A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Letters 1994, 85:205-210.
47. Mullbacher A., Waring P., Tha Hla R., Tran T., Chin S., Stehle T., Museteanu C., Simon M.M. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13950-13955.
48. Naldini A., Sower L., Bocci V., Meyers B., Carney D.H. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. Journal of Cellular Physiology 1998, 177:76-84.
49. Novick D., Rubinstein M., Azam T., Rabinkov A., Dinarello C.A., Kim S.H. Proteinase 3 is an IL-32 binding protein. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:3316-3321.
50. Peng W.J., Yan J.W., Wan Y.N., Wang B.X., Tao J.H., Yang G.J., Pan H.F., Wang J. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. Journal of Clinical Immunology 2012, (Electronic publication ahead of print).
51. Pham C.T. Neutrophil serine proteases fine-tune the inflammatory response. The International Journal of Biochemistry & Cell Biology 2008, 40:1317-1333.
52. Popovic M., Smiljanic K., Dobutovic B., Syrovets T., Simmet T., Isenovic E.R. Thrombin and vascular inflammation. Molecular and Cellular Biochemistry 2012, 359:301-313.
53. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nature Reviews Genetics 2003, 4:544-558.
54. Ramelli G., Fuertes S., Narayan S., Busso N., Acha-Orbea H., So A. Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo. Immunology 2010, 129:20-27.
55. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. The Neuroscientist 2002, 8:586-595.
56. Rott O., Fleischer B., Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. European Journal of Immunology 1994, 24:1434-1440.
57. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nature Reviews Immunology 2010, 10:170-181.
58. Saw S., Kale S.L., Arora N. Serine protease inhibitor attenuates ovalbumin induced inflammation in mouse model of allergic airway disease. PLoS One 2012, 7:e41107.
59. Segal A.W. How neutrophils kill microbes. Annual Review of Immunology 2005, 23:197-223.
60. Siefert S.A., Sarkar R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012, 20:210-216.
61. Subramanian S., Shahaf G., Ozeri E., Miller L.M., Vandenbark A.A., Lewis E.C., Offner H. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metabolic Brain Disease 2011, 26:107-113.
62. Suzuki K., Yano T., Sadzuka Y., Sugiyama T., Seki T., Asano R. Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076 bearing mice. Oncology Reports 2005, 13:1247-1250.
63. Syrovets T., Simmet T. Novel aspects and new roles for the serine protease plasmin. Cellular and Molecular Life Sciences 2004, 61:873-885.
64. Syrovets T., Lunov O., Simmet T. Plasmin as a proinflammatory cell activator. Journal of Leukocyte Biology 2012, 92:509-519.
65. Tani K., Murphy W.J., Chertov O., Oppenheim J.J., Wang J.M. The neutrophil granule protein cathepsin G activates murine T lymphocytes and upregulates antigen-specific IG production in mice. Biochemical and Biophysical Research Communications 2001, 282:971-976.
66. Touil T., Ciric B., Ventura E., Shindler K.S., Gran B., Rostami A. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. Journal of Neurological Sciences 2008, 271:191-202.
67. Trapani J.A. Granzymes: a family of lymphocyte granule serine proteases. Genome Biology 2001, 2(12). REVIEWS3014.
68. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. Journal of Leukocyte Biology 2007, 82:1375-1381.
69. Viret C., Leung-Theung-Long S., Serre L., Lamare C., Vignali D.A., Malissen B., Carrier A., Guerder S. Thymus-specific serine protease controls autoreactive CD4 T cell development and autoimmune diabetes in mice. The Journal of Clinical Investigation 2011, 121:1810-1821.
70. Walport M.J. Complement. First of two parts. The New England Journal of Medicine 2001, 344:1058-1066.
71. Wan X.S., Hamilton T.C., Ware J.H., Donahue J.J., Kennedy A.R. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. Nutrition and Cancer 1998, 31:8-17.
72. Yamasaki Y., Satomi S., Murai N., Tsuzuki S., Fushiki T. Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors. Journal of Nutritional Science and Vitaminology (Tokyo) 2003, 49:27-32.
73. Yanagita M., Kobayashi R., Kashiwagi Y., Shimabukuro Y., Murakami S. Thrombin regulates the function of human blood dendritic cells. Biochemical and Biophysical Research Communications 2007, 364:318-324.
74. Yavelow J., Collins M., Birk Y., Troll W., Kennedy A.R. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:5395-5399.
75. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Seminars in Thrombosis and Hemostasis 2011, 37:362-374.